ERBB2 and breast cancer: This case study presents a patient with locally advanced HER2-positive BC who underwent treatment with a combination of three targeted drugs (Trastuzumab, Pertuzumab and Pyrotinib) in conjunction with chemotherapy, resulting in the achievement of a pathological complete response (pCR) in our department.